Protein engineering strategies for sustained Glucagon-Like peptide-1 Receptor-Dependent control of glucose homeostasis

Diabetes

Volumn 57, Issue 7, 2008, Pages 1926-1934

  Picha, Kristen M ^a   Cunningham, Mark R ^a   Drucker, Daniel J ^b   Mathur, Ashok ^a   Ort, Tatiana ^a   Scully, Michael ^a   Soderman, Avery ^a   Spinka Doms, Tracy ^a   Stojanovic Susulic, Vedrana ^a   Thomas, Beth Ann ^a   O'Neil, Karyn T ^a  

^a CENTOCOR INC   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CNTO 736; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; LACTOFERRIN; TRANSFERRIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE C FOS; PEPTIDE SYNTHESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN ENGINEERING; RODENT; STOMACH EMPTYING; WEIGHT REDUCTION; ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANIMAL; ANIMAL FOOD; C57BL MOUSE; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; HOMEOSTASIS; KIDNEY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION;

ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANIMAL FEED; ANIMALS; CELL LINE; GLUCOSE; HOMEOSTASIS; HUMANS; KIDNEY; LACTOFERRIN; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; OBESITY; PROTEIN ENGINEERING; RECEPTORS, GLUCAGON; TRANSFERRIN;

EID: 48249130928     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1775     Document Type: Article

References (44)

1. Kay BK, Kurakin AV, Hyde-DeRuyscher R: From peptides to drugs via phage display. DDT 3:370-378, 1998
2. Brown LR: Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2:29-42, 2005
3. Kumar TR, Soppimath K, Nachaegarim SK: Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 7:261-276, 2006
4. Sato AK, Viswanathan M, Kent RB, Wood CR: Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17:638-642, 2006
5. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC: Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073-1078, 2005
6. Carter P: Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357, 2006
7. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad SciUSA 84:3431-3438, 1987
8. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV: Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119:1467-1475, 1986
9. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF: Preproglucagon gene expression in pancrea and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11884, 1986
10. Holst JJ, Orskov C, Vagn Nielsen O, Schwartz TW: Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174, 1987
11. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad SciUSA97:6874-6879, 2000
12. Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
13. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 11:1300-1303, 1987
14. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
15. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C: Effects of intravenous GLP-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrin Metab 91:1916-1923, 2006
16. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141:4600-4605, 2000
17. Edvell A, Lindstrom P: Initiation of increased pancreatic islet growth in young normoglycemic mice (umea +/?). Endocrinology 140:778-783,1999
18. Hardikar AA, Wang XY, Williams LJ, Kwok J, Wong R, Yao M, Tuch BE: Functional maturation of fetal porcine b-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 143:3505-3514, 2002
19. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates b-cell apoptosis. J Biol Chem 278:471-478, 2003
20. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408, 2002
21. Farilla L, Bulotta A, Hirshberg B, Calzi SL, Khoury N, Noushmehr H, Bertolotto C, DiMario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149-5158, 2003
22. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M: Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47:806-815, 2004
23. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and b-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830, 2002
24. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100, 2005
25. Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, Achuthanandam R, Spinka-Doms T, Kwok D, Graden D, Volk A, Nesspor T, James IE, Huang C: CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetcs and pharmacodynamics in mice. J Biotechnology 134:171-180, 2008
26. O'Neil KT, Picha K: Human GLP-1 mimetibodies, compositions, methods and uses. Patent Publication: WO 2005097175A2
27. Ritzel U, Leonhardt U, Ottleben M, Ruhmann A, Eckart K, Spiess J, Ramadori G: A synthetic glucagon-like peptide-1 analog with improved plasma stability. J Endocrinol 158:93-102, 1998
28. Xiao Q, Giguere J, Parisien M, Jeng W, St. Pierre SA, Brubaker PL, Wheeler MB: Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40:2860-2869, 2001
29. Bottino R, Fernandez LA, Ricordi C, Lehmann R, Tsan M, Oliver R, Inverardi L: Transplantation of allogeneic islets of langerhans in the rat liver: effects of marophage depletion on graft survival and microenviron- ment activation. Diabetes 47:316-323, 1998
30. Scrocchi LA, Brown TJ, Maclusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258, 1996
31. Baggio LL, Huang Q, Brown TJ, Drucker, D. J: A recombinant glucagon-like peptide (GLP)-1 albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492-2500, 2004
32. Holliger P, Hudson PJ: Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136, 2005
33. Glaesner W, Micanovic R, Tschang S: GLP-1 fusion proteins. Patent Publication: WO 200246227A2
34. Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K: Comparison of the efffects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 125:3109-3114, 1989
35. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP: Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856, 1996
36. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DH, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like petide-1 in the central regulation of feeding. Nature 379:69-72, 1996
37. van Dijk G, Thiele TE, Seeley RJ, Woods SC, Bernstein IL: Glucagon-like peptide-1 and satiety. Nature 385: 214, 1997
38. Larsen J, Hylleberg B, Ng K, Damsbo P: Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24:1416-1421, 2001
39. Kim D, MacConell L, Zhuang D, Kothare PA, Trautman M, Fineman M, Taylor K: Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487-1493, 2007
40. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J, Verhoeven R, Buganova I, Madsbad S: Liraglutide Significantly Improves Glycemic Control, and Lowers Body Weight without Risk of Either Major or Minor Hypoglycemic Episodes in Subjects with Type 2 Diabetes. Matschinsky FM, Banks P, Ed. Washington, DC, American Diabetes Association, 2006, p. A27-A28
41. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea- treated patients wtih type 2 diabetes. Diabetes Care 27:2628-2635, 2004
42. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulonylurea. Diabetes Care 28:1083-1091, 2005
43. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK: Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neuroscience 23:2939 -2946, 2003
44. Kinzig KP, D'Alessio DA, Seeley RJ: The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neuroscience 22:10470-10476, 2002